Polycythemia vera (PV) is a cancer. Specifically, it is classified by the World Health Organization as a myeloproliferative neoplasm, a type of blood cancer in which the bone marrow produces too many red blood cells. That said, it behaves very differently from what most people picture when they hear the word “cancer.” It grows slowly, it’s highly manageable with treatment, and many people live with it for decades.
What “Myeloproliferative Neoplasm” Means
The term sounds intimidating, but it breaks down simply. “Myelo” refers to bone marrow. “Proliferative” means overproduction. “Neoplasm” means abnormal growth, which is the medical definition of cancer. In PV, your bone marrow goes into overdrive, churning out far more red blood cells than your body needs. This thickens your blood, which raises the risk of clots and other cardiovascular problems.
PV often produces excess white blood cells and platelets too, not just red blood cells. The root cause in over 90% of cases is a mutation in a gene called JAK2. This mutation flips a growth signal permanently “on,” so blood cell production never gets the message to slow down. You don’t inherit PV in most cases. The mutation happens during your lifetime in a single bone marrow cell, which then multiplies.
Why PV Doesn’t Look Like Typical Cancer
When people think of cancer, they usually think of tumors, chemotherapy, and a potentially short prognosis. PV doesn’t fit that picture. There’s no solid tumor. The disease progresses slowly, often over many years, and the primary goal of treatment is keeping blood thickness under control rather than eliminating a mass. Many patients are diagnosed incidentally through routine blood work showing an unusually high red blood cell count before they even have symptoms.
The diagnosis is typically confirmed when blood counts are elevated (hemoglobin above 16.5 g/dL in men or 16 g/dL in women), the JAK2 mutation is present, and sometimes a bone marrow biopsy shows characteristic changes. Some people go years without knowing they have PV because the early symptoms, like headaches, itching after a warm shower, or fatigue, are easy to attribute to other causes.
The Real Danger: Blood Clots
The most serious immediate risk of PV isn’t the cancer spreading. It’s blood clots. Thickened blood flows sluggishly and is more prone to clotting, which can cause strokes, heart attacks, deep vein thrombosis, and clots in unusual locations like the veins of the liver or abdomen.
The numbers are significant. In one study of 665 patients from the Mayo Clinic, 25% had experienced a blood clot before their PV was even diagnosed, and another 24% developed one afterward. Risk varies dramatically by individual. Patients stratified as low-risk had a clot rate of only 0.45 per 100 patient-years, while high-risk patients had a rate of 14 per 100 patient-years. After 10 years, roughly 95% of low-risk patients remained clot-free compared to just 18% of high-risk patients. Age over 60 and a history of prior clots are the two biggest factors that push someone into the high-risk category.
How PV Is Treated
Treatment focuses on two things: keeping blood thickness in a safe range and reducing clot risk. The foundation is straightforward. Low-dose aspirin thins the blood slightly, and regular phlebotomy (removing a pint of blood, much like donating blood) brings red blood cell levels down. The target is a hematocrit, the percentage of your blood made up of red blood cells, below 45%. You’ll have this checked regularly, and phlebotomy sessions happen as often as needed to stay under that threshold.
For higher-risk patients, or those who need phlebotomy too frequently, doctors add a medication to slow down the bone marrow’s overproduction. The two most common options are hydroxyurea and interferon. Both reduce blood cell counts effectively, though they have different side effect profiles and your hematologist will tailor the choice to your situation.
If those first-line treatments stop working or cause intolerable side effects, a class of drugs called JAK inhibitors targets the exact genetic defect driving the disease. In a randomized trial comparing the JAK inhibitor ruxolitinib against the best alternative therapy in patients who had failed or couldn’t tolerate hydroxyurea, 43% of those on ruxolitinib achieved a complete response compared to 26% on the alternative. Ruxolitinib also cut thromboembolic events nearly in half and significantly improved symptom burden: 61% of patients saw their symptom scores drop by at least 50%, compared to 30% on standard therapy.
Can PV Progress to Something Worse?
This is one of the reasons PV is classified as a true cancer and not just a benign blood disorder. Over time, PV can transform into more aggressive diseases. The two main concerns are secondary myelofibrosis, where the bone marrow becomes scarred and stops functioning properly, and acute myeloid leukemia (AML), a fast-growing blood cancer.
The risk of leukemic transformation is relatively low: between 2% and 5% at 15 years after diagnosis. The timeline varies enormously from person to person. Research using genomic profiling has identified groups with very different trajectories. Some patients transform within a few years of diagnosis, while others show no transformation even after 12 or more years of follow-up. The median time to transformation ranged from 3 years in the fastest-progressing group to 21 years in the slowest. This wide range is why ongoing monitoring matters even when you feel well.
Living With PV Long-Term
For most people, PV is a chronic condition managed over years or decades rather than a disease with a defined endpoint. With consistent treatment, keeping the hematocrit below 45% and taking aspirin, many patients maintain a quality of life close to normal. The main ongoing burdens are regular blood draws, managing symptoms like fatigue and itching, and the psychological weight of carrying a cancer diagnosis that requires lifelong monitoring.
Three-year overall survival rates in clinical trials exceed 87%, even among patients whose first-line treatment had already failed. For newly diagnosed patients with well-controlled disease, the outlook is considerably better than that. The key is staying on top of blood counts and clot prevention, since the disease itself progresses slowly but its complications, especially blood clots, can strike suddenly.